These results attest the capacity of HMB-PP-expanded and activated γδ T-cells to induce anti-tumor responses in vivo, and support the application of this phosphoantigen in conjugation with low amounts of IL-2 in clinical cancer settings. This evidence concerns the gene IL2 and neoplasm.